Short answer
Axsome Therapeutics, Inc. (AXSM) filed an 8-K current report with the SEC on June 3, 2026 reporting Item 8.01 (Other Events). Axsome settled all SUNOSI (solriamfetol) patent litigation, removing a material legal overhang.
Axsome Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Axsome settled all SUNOSI (solriamfetol) patent litigation, removing a material legal overhang
- Settlement terms determine SUNOSI’s generic-entry timing and Axsome’s remaining market exclusivity
- Exhibit 99.1 contains the operative settlement details and commercial implications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axsome Therapeutics, Inc. 8-K filings
Get the next AXSM 8-K as it lands
Follow AXSM for push alerts, or ask the research agent what this filing means.